SomaLogic

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

Retrieved on: 
Thursday, April 25, 2024
EDT, PDT, Proteomics, Egholm, Doctor of Philosophy, Standard BioTools, Webcast, Event, SomaLogic, Management

Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call

Key Points: 
  • Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call
    SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Company’s long-term strategic plan.
  • “Following the completion of the SomaLogic merger, our management team has conducted a comprehensive review of our business as we continue to execute our strategic growth plan.
  • Egholm continued, “We value the immense contributions of our colleagues and I want to express my sincere gratitude to the members of our team who will be departing Standard BioTools.
  • To participate in the conference call by phone, may do so using one of the following dial-in numbers below:

NeoGenomics Announces Senior Leadership Promotions

Retrieved on: 
Thursday, April 18, 2024
Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Other Health, Health, General Health, Oncology, Harvard Law School, Suffolk University, University, Political science, LIMS, Sigma-Aldrich, Ortho Clinical Diagnostics, Senior, JD, Qualcomm, SomaLogic, NEO, Marketing, Rock (geology), MBA, Growth, Management

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.
  • “Warren and Melody have shown exceptional leadership and performance in their respective roles," said Chris Smith, CEO of NeoGenomics.
  • “As we enter our next phase of growth, these senior leadership appointments should drive operational efficiencies, strengthen commercial synergies, and accelerate innovation through R&D.
  • Prior to NeoGenomics, Stone served as President of Americas at Ortho Clinical Diagnostics and Senior Vice President, Life Sciences Division for MilliporeSigma.

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Standard, Total, Doctor of Philosophy, Investment, News, Table, Supplement, Appendix, Egholm, Instrument, Event, GAAP, SomaLogic, Webcast, Standard BioTools, Research, SBS, Video game

Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.

Key Points: 
  • Standard BioTools will host a conference call and webcast today at 1:30 p.m. PT, 4:30 p.m.
  • ET, to discuss fourth quarter and full year 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP operating expenses, and adjusted EBITDA.
  • Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.

OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
NSCLC, Progression-free survival, ICIS, Toxicity, MD, Immunotherapy, ICI, Royal college, AACR, PD-1, Beaumont Hospital, Lung cancer, Biomarker, SomaLogic, Medicine, Patient, Protein, Oncology, Probability, Machine learning, Plasma, Research, Pharmaceutical industry

BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologist at Beaumont Hospital Dublin, professor at the Royal College of Surgeons in Ireland, and co-author of the abstract.

Key Points: 
  • BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost , a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024.
  • Additionally, biological insights related to treatment resistance and immune-related toxicity will be presented.
  • "We are honored to be selected to present our research at the AACR Annual Meeting, highlighting the capabilities of our PROphet® platform in guiding treatment decisions for NSCLC," said Ofer Sharon, MD, CEO of OncoHost.
  • It is a privilege to contribute to this research for the benefit of the cancer community."

InterDigital appoints Ken Kaskoun as Chief Growth Officer

Retrieved on: 
Monday, February 12, 2024
University, InterDigital, AI, Growth, Old Dominion University, Business development, Bar association, SomaLogic, JD, QTL, Research, IDCC, Management

WILMINGTON, Del., Feb. 12, 2024 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that Ken Kaskoun has been appointed as the company’s Chief Growth Officer, reporting to Liren Chen, President and Chief Executive Officer of InterDigital.

Key Points: 
  • WILMINGTON, Del., Feb. 12, 2024 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a mobile, video and AI technology research and development company, today announced that Ken Kaskoun has been appointed as the company’s Chief Growth Officer, reporting to Liren Chen, President and Chief Executive Officer of InterDigital.
  • An engineer and lawyer by background and an experienced inventor, Ken joins from SomaLogic, a life sciences company, where he was Senior Vice President of Strategy and Business Development.
  • “Ken’s experience in the development of long-term growth strategies for technology research and licensing companies makes him an excellent fit as InterDigital’s Chief Growth Officer,” commented Liren Chen, President and Chief Executive Officer of InterDigital.
  • “With InterDigital’s strong financial performance, our licensing momentum, and our focus on growth in areas such as video and cloud services, we are ideally positioned to capitalize on new prospects and deliver even greater shareholder value.”
    “I am delighted to join InterDigital as Chief Growth Officer at such an exciting time in the company’s development,” Ken Kaskoun said.

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Retrieved on: 
Monday, January 8, 2024
Growth, Investment, SomaLogic, Health, SAN, Doctor of Philosophy, Standard BioTools, Beauty salon

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced Standard BioTools and SomaLogic, Inc. preliminary and unaudited revenue results for the fourth quarter and full year 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB) (Standard BioTools or the Company), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced Standard BioTools and SomaLogic, Inc. preliminary and unaudited revenue results for the fourth quarter and full year 2023.
  • Standard BioTools expects fourth quarter 2023 revenue of approximately $28 million and full year 2023 revenue of approximately $106 million.
  • The Company’s preliminary full year 2023 revenue results represent growth of over 10% in core revenue1 driven by over 40% growth in instrument revenue, in each case as compared with 2022.
  • SomaLogic expects fourth quarter 2023 revenue of approximately $23 million and full year 2023 revenue of approximately $86 million.

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

Retrieved on: 
Friday, January 5, 2024
SomaLogic, Standard BioTools, Research, Health, Doctor of Philosophy, SAN, Growth, Standard, Management

Each SomaLogic stockholder will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned.

Key Points: 
  • Each SomaLogic stockholder will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned.
  • “This is an exciting day as we officially bring together the innovative multi-omic technologies and incredible talent of Standard BioTools and SomaLogic to create one company that is a diversified leader in life sciences tools,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools.
  • Delivering additional meaningful value creation opportunities through a proven model that couples deep large-enterprise life sciences expertise and operating discipline.
  • Carlos Paya, Laura Clague and Martin Madaus – who served on the Standard BioTools Board until the closing of the merger – have resigned from the Standard BioTools Board.

Standard BioTools Stockholders Approve Merger with SomaLogic

Retrieved on: 
Friday, January 5, 2024
Doctor of Philosophy, Special, SomaLogic, Health, SAN, Standard BioTools

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders.
  • “We are pleased with the outcome of today’s Special Meeting and thank our stockholders for their support for this merger,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools.
  • “Together with SomaLogic, we will have an expanded platform to better serve our customers and we believe we will be able to deliver significant shareholder value through enhanced scale and a strengthened balance sheet to fuel future growth.”
    Standard BioTools will file the final vote results, as certified by the independent inspector of election, on a Form 8-K with the U.S. Securities and Exchange Commission.
  • The merger is expected to close on January 5, 2024, subject to satisfaction of certain customary closing conditions.

Madryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special Meeting

Retrieved on: 
Thursday, January 4, 2024
Asset Management, Professional Services, Finance, SomaLogic, Special, Shareholder Meeting

Madryn sent the Board of Directors a legal letter earlier today and asked that all documents relevant to the Transaction be retained as it evaluates its legal options.

Key Points: 
  • Madryn sent the Board of Directors a legal letter earlier today and asked that all documents relevant to the Transaction be retained as it evaluates its legal options.
  • Madryn calls on SomaLogic to finally hold the Special Meeting after hours of delay.
  • Madryn directly asked the Company the following questions in the submission box within the virtual Shareholder Meeting and via email:
    Why has SomaLogic adjourned the Special Meeting multiple times?
  • Madryn believes it is clear that this Board of Directors is not treating shareholders equitably and has opened itself up to liability.

Madryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioTools

Retrieved on: 
Thursday, January 4, 2024
Asset Management, Professional Services, Finance, SomaLogic, Special, Security (finance)

Avinash Amin, Managing Partner of Madryn Asset Management, stated:

Key Points: 
  • Avinash Amin, Managing Partner of Madryn Asset Management, stated:
    “We appreciate that many of our fellow shareholders have been willing to evaluate Madryn’s facts-based analysis of this conflict-ridden and value-destructive Proposed Merger.
  • Any shareholder approached by the Company from here on out should be very skeptical about the outreach and what they hear pertaining to the Proposed Transaction.
  • Ideally, the directors would immediately begin engaging with us about viable alternatives to the Transaction.
  • We stand ready and willing to have a productive dialogue.”
    IF YOU HAVE QUESTIONS ABOUT CHANGING YOUR VOTE, CONTACT MADRYN OR OUR FIRM’S PROXY SOLICITOR